Search results for "DRUG-DRUG INTERACTIONS"

showing 4 items of 4 documents

The impact of polypharmacy and drug interactions among the elderly population in Western Sicily, Italy.

2017

Aim: Primary endpoint was to report polypharmacy distribution in the general population vs ≥65 years old people and to examine the frequency of drug–drug interactions (DDIs) in the Health Local Unit of Palermo, Italy, in relationship with patients’ age. Methods: Drug prescription data for the year 2014 were extracted from the database of the Local Health Unit of Palermo Province, Italy. Patients were divided into five age groups (0–13, 14–64, 65–69, 70–74, and ≥75 year old). The detection of potential DDIs in polypharmacy profiles was performed with NavFarma software (Infologic srl, Padova, Italia), with DDI classification provided by tool Micromedex Drug Reax (Truven Health Analitics, Mich…

DrugMaleAgingPediatricsmedicine.medical_specialtyDatabases Factualmedia_common.quotation_subjectDrug interactionPopulationDrug prescription030204 cardiovascular system & hematologySettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineDrug Utilization ReviewAge groupsElderly populationInternal medicinemedicineClinical endpointHumansDrug Interactions030212 general & internal medicineSettore SECS-S/05 - Statistica SocialeMedical prescriptioneducationSicilymedia_commonAgedPolypharmacyeducation.field_of_studyElderly populationbusiness.industrySignificant differenceAge FactorsMiddle AgedContraindicated drug-drug interactions.Population SurveillanceChronic DiseaseSettore BIO/14 - FarmacologiaPolypharmacyFemaleGeriatrics and GerontologybusinessAging clinical and experimental research
researchProduct

Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients

2021

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic diseases associated with increased morbidity and reduced quality of life. Age may represent a risk factor for adverse events, due to the multimorbidity and polypharmacy, common in elderly patients. Elderly are often not included in clinical trials evaluating efficacy and safety of study drugs for the treatment of inflammatory bowel diseases. Several drugs, such as aminosalicylates, systemic corticosteroids, immunosuppressant drugs, biological drugs and Janus Kinase inhibitors, are available for the management of inflammatory bowel diseases. With the increasing spectrum of therapeutic options, it is th…

safetyPolypharmacydrug-drug interactionsmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInflammatory bowel disease elderly patients safety drug-drug interactionsGastroenterologyDiseaseelderly patientsmedicine.diseaseInflammatory bowel diseaseUlcerative colitisInflammatory bowel diseaseVedolizumabClinical trialUstekinumabInternal MedicinemedicineAdverse effectIntensive care medicinebusinessmedicine.drugMinerva Gastroenterology
researchProduct

Fine-tuning lexical bundles : a methodological reflection in the context of describing drug-drug interactions

2018

This chapter has two major aims. First, it attempts to extend earlier research on recurrent phraseologies used in the pharmaceutical field (Grabowski 2015) by exploring the use, distribution and functions of lexical bundles found in English texts describing drug-drug interactions. Conducted from an applied perspective, the study uses 300 text samples extracted from DrugDDI Corpus originally collected in the Drugbank database (Segura-Bedmar et al. 2010). Apart from presenting new descriptive data, the second aim of the chapter is to reflect on the ways lexical bundles have been typically explored across different text types and genres. The problems discussed in the chapter concern the method…

drug-drug interactionslexical bundlescorpus-driven approachpharmaceutical texts
researchProduct

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use…

2013

This review encompasses the most important advances in liver functions and hepatotoxicity and analyzes which mechanisms can be studied in vitro. In a complex architecture of nested, zonated lobules, the liver consists of approximately 80 % hepatocytes and 20 % non-parenchymal cells, the latter being involved in a secondary phase that may dramatically aggravate the initial damage. Hepatotoxicity, as well as hepatic metabolism, is controlled by a set of nuclear receptors (including PXR, CAR, HNF-4α, FXR, LXR, SHP, VDR and PPAR) and signaling pathways. When isolating liver cells, some pathways are activated, e.g., the RAS/MEK/ERK pathway, whereas others are silenced (e.g. HNF-4α), resulting in…

MAPK/ERK pathwayHealth Toxicology and MutagenesisNF-KAPPA-BReceptors Cytoplasmic and NuclearReview ArticlePharmacologyToxicologyToxicogeneticsNon-parenchymal cells0302 clinical medicineInduced pluripotent stem cellANION-TRANSPORTING POLYPEPTIDECONSTITUTIVE ANDROSTANE RECEPTOR0303 health sciencesGeneral Medicine3. Good healthCell biologymedicine.anatomical_structureLiver030220 oncology & carcinogenesisHepatocyte[SDV.TOX]Life Sciences [q-bio]/ToxicologyInactivation MetabolicClearanceDILIStem cellPLURIPOTENT STEM-CELLSFARNESOID-X-RECEPTORSignal TransductionMechanisms of gene regulationARYL-HYDROCARBON RECEPTORCell signalingPharmacology and ToxicologyHEPATIC STELLATE CELLSBiology03 medical and health sciencesOrgan Culture TechniquesIn vivoCulture TechniquesToxicity TestsmedicineMathematical modeling.AnimalsHumansLiver X receptorDRUG-DRUG INTERACTIONS030304 developmental biologyCryopreservation[INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation3D ModelsCoculture TechniquesHigh-Throughput Screening AssaysSALT EXPORT PUMPGene Expression RegulationHepatic stellate cellHepatocytes[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyPRIMARY RAT HEPATOCYTESMathematical modeling
researchProduct